RECEIVED CENTRAL FAX CENTER

MAR 1 5 2005

PATENT

Attorney Docket No. 05882.0168.CPUS01 (Previously 018501-003100US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gish et al.

App. No.: 09/930,020

Conf. No.: 2304

Filing Date: August 14, 2001

Title:

METHODS OF DIAGNOSIS OF

COLORECTAL CANCER,

COMPOSITIONS AND METHODS OF SCREENING FOR COLORECTAL

CANCER MODULATORS

Art Unit:

1642

Examiner:

Rawlings, Stephen L.

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class muil in an envelope addressed to: Mail Stop RCE, Complissioner for Patents P.O. Box 1450, Alexandria, VA 2224 77455 of this state:

03/15/05 Date

Registration)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Form PTO/SB/08B. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08B be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

Application No. 09/930,020

Filed: August 14, 2001

Page 2

Attyn. Docket No. 05882.0168.CPUS01

This Information Disclosure Statement is being filed prior to the receipt of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application and accompanied with the fee of \$180.00 set forth in §1.17(p), and hence is believed to be timely filed in accordance with 37 C.F.R. §1.97(c)(2). No other fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any additional fees under 37 C.F.R. §§1.16 to 1.21 be deemed necessary for any reasons relating to this document, the Commissioner is hereby authorized to deduct the fees form Howrey Simon Arnold & White, LLP Deposit Account 08-3038 referencing the above-identified attorney docket number.

Respectfully submitted,

HOWREY SIMON ARNOLD & WHITE, LLP

Dated: March 15, 2005

By:

eddy C. Scott, Jr., Ph.D.

Registration No.: 53,573

Customer No.: 22930

HOWREY SIMON ARNOLD & WHITE, LLP 321 N. Clark Street, Suite 3400 Chicago, IL 60661 (312) 595-1239 (main) (312) 846-5621 (direct)

(312) 595-2250 (fax)

Sheet

3125951766

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information timess it contains a valid clied clied contains a valid clied contains a v					
Substitute for form 1449/PTO	Complete if Known				
	Application Number	09/930,020			
INFURMATION DISCLOSURE	Filing Date	August 14, 2001			
STATEMENT BY APPLICANT	First Named Inventor	Kurt C. Gish			
(Use as many sheets as necessary)	Group Art Unit	1642			
	Examiner Name	Stephen L. Rawlings			
Sheet of	Attorney Docket Number	05882.0168.CPUS01			

		NON PATENT LITERATURE DOCUMENTS	-
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	Τ²
	Cl	Fetrow, J.S., et al., "Method For Prediction Of Protein Function From Sequence Using The Sequence-To-Structure-To-Function Paradigm With Application To Glutaredoxins/Thioredoxins And T1 Ribonucleases," Journal Mol. Biol., Vol. 281, No. 5, pp. 949-968 (September 4, 1998)(Abstract)	
•	C2	Rost, Burkhard, "Twilight Zone of Protein Sequence Alignments," Protein Engineering, Vol. 12, No. 2, pp. 85-94 (1999)	_
			+
			\perp
			$\frac{1}{2}$
			_
			+
			+
	- - -		十

Examiner	Date .			
	Considered			
Signature Considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not				
*EXAMINER: Initial if reference considered, whether or not clause is in conformance with the constant of the control of the co				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, helude copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is stracted.

'This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this hurden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FLES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Potents, P.O. Box 1450, Alexandria, VA 22313-1450. 1450. Alexandria, VA 22313-1450.

> If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2. DM_US\8173829.v1